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ABSTRACT
Objective: Type I interferon (IFN-I) responses are broadly associated with autoimmune 
disease including SLE. Given the cardinal role of autoantibodies in SLE, we investigated 
whether a B cell-specific IFN assay might correlate with SLE activity.
Methods: B cells and PBMCs were stimulated with IFN-I and IFN-II. Gene expression 
was scrutinized for pathway-related membrane protein expression. A flow-cytometric 
assay for tetherin (CD317), an IFN-induced protein ubiquitously expressed on leucocytes, 
was validated in vitro then clinically against SLE diagnosis, plasmablast expansion, and 
BILAG-2004 score in a discovery cohort (156 SLE; 30 RA; 22 healthy controls). A second 
longitudinal validation cohort of 80 patients was also evaluated for SLE flare prediction.
Results: In vitro, a close cell-specific and dose-responsive relationship between IFN-I 
responsive genes and cell surface tetherin in all immune subsets existed. Tetherin 
expression on multiple cell subsets was selectively responsive to stimulation with IFN-I 
compared to IFN-II and -III. In patient samples from the discovery cohort memory B-cell 
tetherin was best associated with diagnosis (SLE/HC: effect size=0.11, p=0.003; SLE/RA: 
effect size=0.17, p<0.001); plasmablast numbers in rituximab-treated patients (Rho=0.38, 
p=0.047) and BILAG-2004. Association were equivalent or stronger than interferon score 
or monocyte tetherin. The validation cohort confirmed this relationship with memory B-cell 
tetherin predictive of future clinical flares (Hazard Ratio=2.29 (1.01–4.64), p=0.022).
Conclusion: Memory B cell surface tetherin, a B cell-specific IFN assay, was associated 
with SLE diagnosis, disease activity, and predicted flares better than other cell subsets or 
whole blood assays in independent validation cohorts.
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INTRODUCTION
Type I interferons (IFN-I) are a highly pleotropic group of cytokines that link the innate 
and adaptive immune systems and play a pivotal role in autoimmune disease(1-3). All 
nucleated cells express IFN-I receptors and will express a set of interferon-stimulated 
genes (ISGs) after exposure to IFN-I(4, 5). Hundreds of effects of IFN-I on various 
cellular processes, interactions and disease processes have been described. A challenge 
in the assessment of IFN-I response in an individual disease is therefore ensuring the 
appropriate cellular response can be detected within this complex system.
IFN-I proteins are unstable in blood and not easily detected even in monogenic 
interferonopathies with known high IFN-I production, possibly due to their efficient binding 
to the abundant IFN receptor(6). IFN-I activity is therefore usually measured using 
expression of ISGs in whole blood. We previously analyzed in ISG expression in sorted 
cells from SLE (a prototypic IFN-medicated disease) and healthy individuals and reported 
that in both groups ISG expression was markedly higher in monocytes compared to other 
circulating immune cells, which therefore dominates ISG assays that use unsorted 
blood(7).
These differing levels of ISG expression in cell populations may be due to the rate of 
turnover of each population, their trafficking to sites of higher IFN-I production in inflamed 
tissues, or priming for IFN-I response by other inflammatory mediators. In autoimmunity, 
IFN-I assays may have value to predict flares, and response to a range of different 
targeted therapies(8). However, existing whole blood IFN biomarkers show poor or 
uncertain correlation with disease activity(9-11).  
The measurement of IFN-I status using whole blood ISG expression has two key 
weaknesses in interpreting pathogenic processes. First, changes in expression may 
reflect expansion or contraction of certain circulating leukocyte populations(12, 13) that 
differ in their level of ISG expression. This characteristically occurs in inflammatory 
diseases. In the case of SLE, lymphopenia is almost universally seen(14). So, any 
difference in whole blood gene expression may not necessarily indicate a change in 
production or exposure to IFN-I.A
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Second, analyzing whole blood ISG expression does not allow detection of key 
pathogenic processes among the noise of other, less relevant, effects of IFN-I on biology. 
For example, B cells are a key mediator in SLE(15, 16). IFN-I stimulates B cells to 
differentiate into plasmablasts which are expanded in SLE and correlate with disease 
activity(17, 18). We previously demonstrated that the rate of plasmablast regeneration 
post-rituximab predicts clinical outcome(19). We also previously showed that IFN-I 
imprints plasma cells for the secretion of the proinflammatory molecule ISG15(17). 
Assessment of IFN-I activity in unsorted blood gives limited information about the degree 
to which B cells have specifically been stimulated by IFN-I. Further, gene expression 
assays do not prove that a phenotypic change in target cells has occurred – there has 
been no widely used biomarker for IFN response at a protein level. This may be one 
reason why some patients classified as Interferon signature low have responded well to 
interferon-blocking therapy(20).
In order to resolve these problems, we developed a flow cytometric assay to allow 
measurement of IFN-I response in individual cells without the need for cell sorting. We 
measured the expression of Tetherin (BST2, CD317), a GPI-anchored protein with a 
unique topology which is ubiquitously expressed on the surface of nucleated cells. This 
molecule is prominent in viral immunology and encoded by a commonly-measured ISG 
expressed in all leucocytes (4, 5, 21-23). Unlike most ISGs, BST2 encodes a cell surface 
protein and can be easily measured in patient samples by flow cytometry. Siglec-1 is 
another flow cytometric IFN-I biomarker previously described(24, 25). However, Siglec-1 
is only expressed on monocytes so resolves the issue of changes in size of cell 
populations but does not allow interrogation of individual cell subset IFN-I responses, 
including the key B cell populations that are strongly linked to clinical and experimental 
disease.(26-28)
We hypothesized that a dominant pathogenic role of IFN-I in SLE is its effect on B-cells, 
promoting plasmablast differentiation and clinical disease. Our reasons for addressing B 
cells as a particular cell of interest in SLE were: (i) SLE is associated with autoantibodies, 
which are made by B cells; (ii) there are a number of susceptibility loci for SLE in genes 
with important roles in B cell signalling and function, such as LYN, BLK, BANK1, A
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PTPN22, TNFAIP3, TNIP1](29); (iii) the only targeted therapy licensed for SLE targets B 
cells specifically. Using in vitro stimulation and sorted cells from SLE patients and healthy 
individuals we showed that Tetherin accurately captures cell-specific responses to IFN-I. 
A crucial issue in biomarker research is demonstrating that biomarkers are predictive, 
correlate with a range of outcomes and can be reproduced in validation studies. In our 
studies, longitudinal analysis of discovery and validation cohorts showed that memory B 
cell tetherin more accurately correlates with plasmablast expansion, clinical features of 
disease and predicted flares better than monocyte tetherin or whole blood ISG 
expression.
MATERIALS AND METHODS
The SLE discovery cohort samples included 156 consecutive SLE patients as well as 25 
age-matched healthy controls (HC) and 30 active ACPA-positive ANA-negative RA 
patients (DAS28) =3.9, 95% (CI 3.23–4.56) as a non-SLE inflammatory disease control. 
An independent validation cohort consisted of 80 SLE patients recruited and studied 
longitudinally (total n=236). Disease activity was assessed at the time of sampling using 
the British Isles Lupus Assessment Group (BILAG-2004)(30). Validation cohort patients 
were also followed up for subsequent flare (BILAG A or B). SLE patients’ demographics 
and disease activity are shown in (Table S1). Patients with acute or chronic viral infection 
at the time of blood sampling were excluded from this study. All individuals provided 
informed written consent and this research was carried out in compliance with the 
Declaration of Helsinki. The patients’ blood samples used for this study were collected 
under ethical approval, REC 10/H1306/88, National Research Ethics Committee 
Yorkshire and Humber–Leeds East, and healthy control participants’ peripheral blood 
was collected under the study number 04/Q1206/107. All experiments were performed in 
accordance with relevant guidelines and regulations. The University of Leeds was 
contracted with administrative sponsorship. 
The full details of methods see online Supplementary file and a previously published 
methodology paper(7). 
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RESULTS
BST2/Tetherin as a cell-specific phenotypic biomarker of IFN-I response
Global gene expression profiles showed that many ISGs were responsive to both IFN- 
and IFN- while other ISGs responded specifically to IFN- (7, 17). We therefore tested 
the influence of IFN- (IFN-I) and IFN- (IFN-II) on 31 of most common reported ISGs by 
qPCR analysis (TaqMan) on B-cells in vitro as previously described (17) (Supplement 
figure S1). Results from in vitro stimulation confirmed that BST2 was in the ISG group 
predominantly responsive to IFN-I.
For this reason, we applied multi-parameter flow cytometry analysis to detect and 
quantify the tetherin on PBMCs described in supplementary methods. We used a gating 
strategy allowing to define: T-cells, NK-cells, monocytes as well as B-cell subsets: naïve, 
memory and plasmablasts. For each of these populations mean fluorescence intensity 
(MFI) of tetherin is shown compared to isotype control (Figure 1A). We compared cell-
surface tetherin protein levels by flow cytometry versus BST2 gene expression by qPCR 
for these six FACS-sorted cell subtypes from ten SLE patients and six HC (total n=16). 
BST2 gene expression levels were substantially positively correlated with tetherin protein 
levels on the cell surface within each of the subtypes (Figure 1B). These data confirm 
that varying level of tetherin/BST2 expression between cell subsets and differences 
between individuals may be captured using flow cytometry without the need for cell 
sorting. Furthermore, we compared tetherin MFI on monocytes, B-cells and T-cells with 
Siglec-1 in samples from 25 SLE patients and 5 healthy controls. We confirmed that 
tetherin correlated with Siglec-1 only on monocytes because other cell subsets lack 
expression of Siglec-1 (Figure S2).
Dose response of tetherin to IFN-I, IFN-II, and IFN- III 
We tested dose-response relationship of tetherin on all circulating cell subsets towards 
IFN-, IFN- (both IFN-I), IFN- (IFN-II), and IFN- (IFN-III). HC PBMCs were stimulated 
for 48h with doses ranging from 0.1–1000 ng/mL then analyzed by flow cytometry. 
Interestingly, tetherin MFI on memory B-cells was the most responsive to increasing A
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doses of IFN- and IFN-, with more modest response to IFN- and IFN-. Although 
monocytes had the highest expression of tetherin in patient samples and the highest 
basal expression in unstimulated HC PBMCs, they showed much lower fold change in 
tetherin response to IFN-I stimulation (Figure 1C). Furthermore, purified B-cells response 
curves for BST2 gene expression and tetherin protein MFI revealed a dose-response 
closely matched response to IFN- (Figure 1D). We concluded that tetherin MFI by flow 
cytometric analysis could accurately measure change in expression of BST2 in response 
to IFN-I and could be used to capture IFN-I exposure in a dose- and cell-specific manner.
B-cell surface tetherin protein levels best demonstrate disease-associated IFN response 
in SLE
We next compared tetherin protein expression in immune cell subsets in SLE patients 
and HC to determine which cell subset would demonstrate disease-associated change in 
IFN response best. Using all discovery cohort data from SLE and HC, tetherin protein 
levels were compared between groups across cell subtypes by flow cytometry results 
summarized (Table 1, upper panel).
Tetherin levels differed significantly between cell subtypes within SLE, being highest for 
monocytes, 20% of monocyte level in T-cells, and 78% of monocyte level in plasmablasts 
(all p<0.001). Comparing between SLE and HC groups showed that tetherin MFI on 
monocytes did not significantly differ from HC (SLE:HC ratio 1.19, P=0.293), whereas a 
significant higher level was seen in in SLE for all other subsets (ratios 1.37–1.57, all 
P<0.05). Comparing the between group ratio of each subset against that for monocytes 
showed that the disease-associated increase of memory B-cell tetherin showed the 
greatest difference than monocytes’ (P=0.046).
Rituximab treated SLE patients could confound accurate measurement of B-cell 
phenotype in these patients. We therefore repeated these analyses in rituximab-naïve 
patients (Table 1, lower panel). In rituximab-naïve patients (n=58), the largest disease-
associated increase in tetherin expression was seen in naïve (1.53) and memory B-cells 
(1.47). These ratios for naïve and memory B-cells were significantly different from 
monocytes (P=0.006 and P=0.013 respectively). These results indicate that differences in A
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IFN response at a protein level between cell subsets are clinically relevant and B-cell 
tetherin is the most clinically relevant parameter.
Tetherin and Interferon gene expression assays
Overall comparisons of tetherin measured on memory B cells and two validated 
interferon gene expression scores are shown in Figures S3 and S8. As expected given 
the difference in cell populations analyzed, there was a significant correlation but a 
degree of disagreement between these assays.
Clinical validation of Tetherin IFN assay: diagnosis
We compared the performance of the tetherin flow cytometric assay in distinguishing 
between patients with a diagnosis of SLE, active RA, or HC. Given our previous results, 
for this analysis we only included rituximab-naïve patients controlled for age (Figure 2). 
The full statistical table is shown in the Supplement (Table S2). We considered effect 
sizes to be small (0.01), medium (0.06) or large (0.14) as described by Cohen (31). 
Tetherin data revealed a marked difference between cell subsets. Monocyte tetherin did 
not differentiate SLE from healthy control at all with ratio 1.19 (0.87–1.61) and effect size 
0.03. T-cells and NK-cells had moderate effect sizes of 0.06 each. However, naïve and 
memory B-cell subsets had medium to large effect size of 0.11 with ratios of 1.63 (1.26 –
2.11) and 1.59 (1.21–2.09) respectively.
Tetherin was able to differentiate SLE from other inflammatory disease when compared 
with active RA. Tetherin on monocytes had no diagnostic function with ratio 1.37 (1.00–
1.88) and effect size 0.03. However, all other cell subsets had moderate to large effect 
sizes ranging from 0.14 to the largest for plasmablasts at 0.23, with ratio 2.20 (1.66–
2.93).
Clinical validation of IFN assays: disease activity and autoantibodies
For disease activity, we investigated the association between the number of active organ 
systems (BILAG domains scoring A, B, or C) per patient compared to tetherin on cell 
subsets as well as our recently described IFN score A, which comprises of 12 IFN-I 
selective ISGs (7). We controlled for age in all SLE patients (164 observations in 124 A
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patients). The number of active domains was categorized 0 (n=22), 1 (n=54), 2 (n=57) or 
≥3 (n=31).
At the 10% level of significance, disease activity was associated with IFN Score A (R2 = 
0.08, P=0.027) and tetherin surface expression on T-cells (R2=0.07, P=0.007), NK-cells 
(R2=0.09, P=0.001), memory B-cells (R2=0.09, P=0.006) and plasmablasts (R2=0.06, 
P=0.020). The degree of association was weaker and hence non-significant for 
monocytes (R2 = 0.04, P=0.179) and naïve B-cells (R2=0.04, P=0.103).
For IFN Score A, the relationship with disease activity was not linear. The only significant 
association between the score and disease activity was attributable to patients with the 
most severely active disease (≥3 domains). A similar, although non-significant, pattern 
was observed for tetherin on monocytes. In contrast, there was a linear relationship 
between memory B-cell tetherin and disease activity with a stepwise increase in 
expression for each increase in number of active domains (Figure 3A). We did not expect 
a strong correlation between tetherin on memory B cells and IFN Score in unsorted 
PBMCs: since memory B cells are only ~2% of PBMCs these assays are not trying to 
measure the same biological effect. We found a moderate correlation (Spearman’s R= 
0.356, P<0.0001) (Figure S3). 
To investigate whether the difference between IFN-assays was because of the type of 
organ system affected, we analyzed the two most commonly affected domains 
(mucocutaneous and musculoskeletal) in combination, excluding patients with activity 
(BILAG A, B or C) in any of the other domains. Although there was a significant 
relationship between each IFN-assay and overall disease activity, the relationship with 
IFN-assays varied between these two organ systems (Figure 3B). For IFN Score A, 
increased expression was only seen with mucocutaneous disease activity. While, for 
tetherin on monocytes, increased level was observed only in patients with 
musculoskeletal disease activity. This may explain why this assay does not show a linear 
relationship with disease activity. However, memory B-cell tetherin had a more consistent 
relationship with disease activity in both organ systems. The level of tetherin was lowest 
in patients in clinical remission, higher in patients with active disease in a single organ, 
and highest in patients with active disease in both organs. A
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The numbers of patients with other active organ domains were more limited. Of patients 
with no activity in other domains, 12 had active (A or B) hematological disease (immune 
mediated hemolysis or thrombocytopenia). Memory B-cell tetherin MFI on the active and 
inactive hematology groups was 1954 vs. 1494 respectively, P=0.005. Eight patients had 
active renal disease. Comparing these 8 active renal patients versus inactive disease 
also revealed a significant increase in tetherin on memory B-cells (tetherin MFI 2625 vs. 
1562, P=0.005). Tetherin levels were not associated with glucocorticoid prescription 
(Figure S4).
In our rituximab-naïve patients, there was a positive correlation (R=0.412, P=0.0001) 
between memory B cell tetherin and autoantibodies, summarized as the number of 
extractable nuclear antigen subtypes (Figure S5).
For additional comparison to alternative IFN assays, we also calculated a 5-gene IFN 
signature as “Type I IFN positive” or “Type I IFN negative” as published by Higgs et al 
(32). Results are shown in supplemental figure S6. The majority of the SLE patients were 
in the Type I IFN positive subgroup. As expected, this subgroup had worse BILAG 
disease activity (p=0.016). To test whether tetherin gave additional information in 
comparison to the gene expression status, we therefore re-tested the association of 
tetherin with BILAG within the Type I IFN positive subgroup. We still found a significant 
association between tetherin and disease activity (Spearman’s R=0.321, p=0.038), which 
could not be measured by using the more standard assay. This indicates that memory B 
cell Tetherin gives additional clinically relevant information compared to the IFN signature 
alone.
Clinical validation of IFN assays: plasmablasts
Lastly, in the discovery cohort, we used plasmablast count to represent current B-cell 
activity and differentiation. IFN-I is known to promote the differentiation of memory B-cells 
into plasmablasts (33). We have previously shown that post-rituximab early rapid 
population of plasmablasts led to an early clinical relapse(34, 35). We hypothesized that 
the memory B-cells tetherin level would correlate with circulating plasmablasts numbers 
post-rituximab reflecting an increased rate of differentiation secondary to IFN-I. The A
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results are shown in Table 2. In rituximab-naïve patients, no relationship was revealed 
between any tetherin IFN-assay and plasmablast count, while in post-rituximab patients 
there was no correlation with tetherin on monocytes, NK or T-cells. But memory B-cell 
tetherin was significantly correlated with numbers of plasmablasts after (Spearman’s 
R=0.38, P=0.047) as well as inversely correlated with time to clinical relapse (R=0.623, 
P=0.022). To further explore whether tetherin surface protein expression was associated 
with the induction of relevant pathogenic pathways in B cells, we evaluated two 
transcripts for downstream plasmablast function; IgJ, for antibody synthesis in all 
samples, and ISG15 for ISG15 protein secretion in sorted memory B cells. Both of these 
transcripts showed a significant correlation with the flow cytometric measurement of 
memory B cell tetherin MFI (see supplementary figure S7).
Independent Validation Cohort
The independent validation cohort consisted of a further 80 patients with SLE recruited 
and studied prospectively. Memory B-cell and monocyte tetherin levels were measured 
using fresh lysed whole blood in an independent accredited diagnostic laboratory. 
Disease activity was measured at the time of sampling using BILAG-2004. Patients were 
followed up for subsequent flare (BILAG A or B).
We found a similar relationship between tetherin and disease activity as in our discovery 
cohort. For memory B-cell tetherin, there was a significant relationship between number 
of organ domains and active disease (P=0.0005) but no relationship with monocyte 
tetherin (P=0.759, Figure 3C). There was a significant association between global BILAG 
score and memory B-cell tetherin (Spearman’s R=0.503, P<0.0001) but no association 
with monocyte tetherin (R=0.058, P=0.627, Figure 3D). Additionally, in this cohort we 
demonstrated that in patients in clinical remission at the time of sampling (n=36), memory 
B-cell tetherin predicted time to clinical flare. In multivariable cox-regression analysis 
including memory B-cell tetherin, monocyte tetherin and age, memory B-cell tetherin was 
a significant predictor of subsequent BILAG A/B flare (Hazard Ratio=2.290, 95% CI 
1.013–4.644, P=0.022). Monocyte tetherin did not significantly predict flare (Hazard 
Ratio=0.814, 95%CI 0.580-1.141, P=0.231, Figure 3E). In conclusion, we independently A
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confirmed that disease activity is related to IFN-I response in memory B-cells measured 
using tetherin, and further, that this is predictive of clinical outcome.
DISCUSSION
In this study we have demonstrated the value of a novel cell-specific biomarker based on 
the IFN-inducible protein tetherin, using in vitro methods and clinical studies in humans. 
We showed that flow cytometric measurement of cell surface tetherin on memory B-cells 
captures cell-specific IFN-I response, is dose-responsive, and has a strong and 
consistent relationship with disease activity, B-cell activity and time to flare in two SLE 
cohorts. These results are important because IFN-I and B cells have a role in many 
autoimmune diseases and their measurement has potential to stratify outcomes and use 
of therapies, but previous studies yielded conflicting results(36).
Better biomarkers are needed in SLE. EULAR Treat-to-target recommendations advise 
treating to a target of low disease activity, while minimizing exposure to 
glucocorticoids(37). Predictors of a severe disease trajectory or flares are needed to 
achieve this. Response to conventional and targeted therapies in SLE and related 
diseases is variable and re-classification of autoimmune diseases according to 
pathogenic mechanisms instead of clinical features has been proposed(36).
The crucial role for IFN-I in the pathogenesis of SLE and related diseases is indicated by 
genetic susceptibility and monogenic interferonopathies as well as evidence of over-
expression(36). As such, it has face validity as a stratification biomarker. Existing studies 
indicate the potential value of measuring IFN-I in diagnosis and prediction of flares. IFN-I 
biomarkers may also predict clinical response to TNF-blockade, B cell depletion and IFN-
I-blockade in RA and SLE(36).
Nevertheless, there are limitations to previous approaches to measuring IFN-I activity 
and some previous results have been contradictory. Direct measurement of IFN-I protein 
is limited by the number of different ligands and instability in serum, with most cell types 
expressing the type I IFN receptor. A recent improvement was the use of single-molecule 
arrays (Simoa). The higher sensitivity of Simoa allows reliable measurement of IFN-α (6). A
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However, this is currently expensive and limited in availability and has not been validated 
against clinical outcomes. When using ISG expression based methods, another issue is 
the effect of other IFN subtypes or other inflammatory mediators. ISGs are known to fall 
into distinct subsets, which may be due to the effect of IFN-II (7, 9). We previously 
showed that there are different patterns of ISG expression in different autoimmune 
diseases. In the present paper we confirmed that tetherin is selectively responsive to IFN-
I and we included ANA-negative RA as an inflammatory disease control (we did not see 
any elevation of tetherin in our RA patients as others have reported for an interferon 
signature, but our selection of only ANA-negative cases may be significant here rather 
than differences in the biomarkers).
While candidate biomarker discoveries in autoimmunity are numerous, a significant 
challenge is in validation in clinically relevant contexts (38). An important aspect of our 
work is the degree of pre-clinical and clinical validation. We have shown two types of 
validation to demonstrate that tetherin reflects cellular response to Type I interferon. We 
have demonstrated a correlation with existing validated interferon assays. However such 
concurrent validity studies are limited by the potential imprecision of the interferon scores. 
These may be affected by changes in the cellular composition of the sample or other 
subtypes of interferons. Moreover, tetherin assesses a specific subsets response to 
interferon (we have shown memory B cells), while interferon scores assess a mixed 
population of cells and will be influenced by other cell types. For these reasons, the more 
important demonstration that tetherin reflects cellular response to Type I interferon is in 
vitro stimulation assays. We show a dose-responsive relationship to Type I interferon in 
multiple cell subsets, far exceeding response to Type II interferon. Our data therefore 
demonstrate good face and construct validity, as well as concurrent and prospective 
criterion validation and feasibility in a routine clinical setting. We also present validation 
against a range of different clinical and longitudinal endpoints. 
Cell specific measurement based on flow cytometry has been demonstrated previously 
using expression of Siglec-1, another cell surface protein convenient for flow cytometry 
that is expressed by monocytes. Monocyte Siglec-1 has been shown to correlate with 
disease activity as well as predict autoimmune congenital heart-block (25, 39, 40). This A
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was a significant advance in analysis of interferon status. In the present work we advance 
this principle further by using a marker expressed on all circulating cells. Tetherin 
captures the same information as Siglec-1 on monocytes, but also evaluates other cell 
subsets. We have shown that results from these different subsets vary, with the strongest 
clinical correlation for memory B cells. This has distinct advantages when there is 
particular interest in a specific cell population, such as with the B cell directed therapies 
rituximab and belimumab in SLE. B cell response to IFN-I is crucial in SLE. 
While there were many associations between tetherin protein expression and clinical 
features of SLE, tetherin on memory B cells seemed to be particularly important. This 
marker correlated best with clinical features, and was the only marker to be associated 
with plasmablast number. After B cell depletion with rituximab, there is a highly variable 
rate of plasmablast repopulation that predicts clinical relapse. Understanding the 
determinants of these repopulation patterns may reveal upstream factors controlling B 
cell autoreactivity. One previous paper reported a relationship between serum BAFF 
titres and numbers of plasmablasts at relapse(41). However, BAFF may not be the only 
factor. IFN-I also promotes B cell activation and differentiation into plasmablasts and 
plasma cells (28, 42). This may include direct influences, for example in animal models 
IFN-I influences BCR and TLR-mediated response to self-nuclear antigen. Our work 
provides data in the human disease to support this observation(43, 44). Additionally, IFN-
I induces a plasma cell phenotype that secretes ISG15 with additional pro-inflammatory 
effects(17).  In the present study we found that memory B cell tetherin correlated with 
plasmablast expansion after rituximab. A plasmablast signature was recently shown to be 
a strong biomarker for SLE and we and others previously showed that plasmablast 
expansion after rituximab was strongly predictive clinical relapse(19, 45, 46). This was 
further supported by correlation between memory B cell tetherin and transcripts 
representing disease-relevant B cell dysfunction.
The tetherin biomarker has some limitations. First, although this flow cytometric assay 
avoids confounders that may affect ISG expression scores, analysing a single interferon-
inducible transcript may be more susceptible to the influence of other inflammatory 
stimuli, which we cannot exclude based on these results. However, our data comparing A
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SLE with the RA disease control are very consistent with those we observed using 
interferon scores with a clear difference in IFN Score A and Tetherin expression between 
SLE and RA. Tetherin, like all IFN-I biomarkers, may be influenced by acute or chronic 
viral infections, which was excluded from this study. It may be more difficult to perform 
flow cytometry in some situations. However, with widespread use of flow cytometry in 
cell-targeted therapies in autoimmunity and oncology as well as in routine monitoring of 
HIV, addition of tetherin cell surface staining is a highly cost-effective test. Tetherin may 
be analyzed in combination with B-cell and plasmablast flow cytometry to stratify both B-
cell and IFN-I blocking therapy.
In summary, we describe measurement of the interferon-inducible protein tetherin on B 
cells as a cell-specific biomarker with a number of advantages and widespread 
applications in clinical and laboratory research in this rapidly expanding area of 
immunology.
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FIGURES TITLES AND FOOTNOTES:
Figure 1. Tetherin is a scalable cell specific measure of IFN-I response. (A) Gating 
strategy for flow cytometric assessment of tetherin on immune cell subsets. An example 
flow cytometry analysis plot for analysis of tetherin protein expression on individual 
immune cell subsets is shown. Forward (FSC-A) and side scatter (SSC-A) were used to 
define lymphocytes and monocytes. B-cells were defined as CD19+ lymphocytes and 
subdivided into naïve, memory and plasmablast subsets using CD27 and CD38. T-cells 
were defined as CD3+ and NK-cells as CD3- CD56+ lymphocytes. The mean 
fluorescence intensity (MFI) of tetherin is shown compared to isotype control. (B) In order 
to validate tetherin as a cell-specific marker, tetherin protein expression was compared 
with expression of its gene BST2 in various immune cell subsets. Unsorted PBMCs were 
analyzed using flow cytometry for surface tetherin protein on each subset (y axis) and 
correlated with gene expression data for BST2 from the FACS sorted subset (x axis). 
There was a strong correlation between gene expression and protein within each subset 
allowing differences in ISG expression between cell subsets to be measured without-cell 
sorting (Monocytes R=0.47, P=0.064; T-cells R=0.61, P=0.012; NK cells R=0.63, P0.008; 
Naïve B-cells R=0.63, P0.009;  Memory B-cells R=0.78, P0.001; Plasmablasts R=0.58, 
P0.018)  (C) HC PBMCs were stimulated with increasing doses of IFN-, IFN- , IFN-, 
and IFN- then each subset was evaluated with flow cytometry for mean fluorescence 
intensity of tetherin of memory B-cells (solid circles, solid curves) and Monocytes 
(Triangles, dashed curves) (n=3) (D) Sorted B-cells were stimulated in vitro with 
increasing doses of IFN- and then evaluated with flow cytometry for mean fluorescence 
intensity of tetherin (red line) as well as expression of its gene, BST2. We found a parallel 
increase in each markerA
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Figure 2. Comparison of tetherin flow cytometric IFN assay against diagnosis. Age-
adjusted differences between patients with SLE (red) and patients with active RA 
(DAS28>3.2; blue) or healthy controls (white). cell surface BST2/tetherin protein levels 
from cell subtypes identified through flow cytometry of PBMCs. Effect sizes (partial eta 
squared) indicate which of the variables differed to the greatest extent between the 
different groups. We considered effect size 0.01 to be small, 0.06 to be medium and 0.14 
to be large (31).
Figure 3. Association between IFN assays and disease activity in SLE. (A) 
Discovery cohort: association between different IFN assays and number of organ 
systems (domains) with active disease 164 observations in 124 SLE patients). IFN score 
shown as 2-dCT (i.e. taller bars represent higher expression) with 90% CI. Dotted lines 
and shaded areas represent mean and 90% CI of 23 healthy controls (HC). Interferon 
Score was increased in patients with ≥3 active domains but not in patients with 1 or 2 
active domains compared to 0 (remission). Tetherin measured on memory B-cells 
demonstrated a more consistent stepwise increase with increasing disease activity. (B) 
Discovery cohort: association between different IFN assays and musculoskeletal and 
mucocutaneous disease activity. Disease activity was defined as Active (BILAG A or B) 
or Inactive (BILAG D or E). Patients with activity in other organs were excluded. For 
Interferon Score there were inconsistent relationships with disease activity, with an 
increase with skin involvement, but not musculoskeletal involvement alone. For monocyte 
tetherin increased protein expression was seen with musculoskeletal disease activity but 
not for skin activity alone. Tetherin measured on memory B-cells demonstrated a 
consistent relationship with both common types of clinical disease. (C) Validation cohort 
(n=80): Bar charts show that association between tetherin and number of active organ 
domains was similar to the discovery cohort, analysed as in (A). (D) Scatter plots show 
association between overall disease activity (BILAG Global score) and tetherin. There 
was a significant association between BILAG Global score and tetherin on memory B-
cells, but not with tetherin on monocytes.  (E) Tetherin on monocyte tetherin did not 
(Hazard Ratio=0.814, 95%CI 0.580-1.141, P=0.231) while tetherin on memory B-cells A
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significantly predicts subsequent clinical flare (Hazard Ratio=2.290, 95% CI 1.013–4.644, 
P=0.022).
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Table 1: Tetherin levels in Cell Subsets in SLE patients and controls
All patients
SLE
n=113
Within-SLE, between 
subtypes 
Ratio (90% CI), P value
HC
n=17
Between-group 
SLE:HC 
Ratio (90% CI), P value
Between-group, between 
subtype 
Ratio (90% CI), P value
Monocytes 3388 Reference 2837 1.19 (0.91, 1.58), P = 0.293 Reference
T-cells 687 0.20 (0.19, 0.22), P < 0.001 475 1.45 (1.17, 1.79), P = 0.005 1.21 (1.00, 1.46), P = 0.092
NK-cells 1129 0.33 (0.31, 0.36), P < 0.001 824 1.37 (1.09, 1.72), P = 0.024 1.15 (0.94, 1.40), P = 0.258
Naïve B-cells 1118 0.33 (0.30, 0.36), P < 0.001 712 1.57 (1.22, 2.03), P = 0.004 1.32 (1.03, 1.68), P = 0.062
Memory B-cells 1586 0.47 (0.43, 0.50), P < 0.001 1033 1.53 (1.23, 1.92), P = 0.002 1.29 (1.04, 1.58), P = 0.046
Plasmablasts 2650 0.78 (0.72, 0.84), P < 0.001 1813 1.46 (1.15, 1.86), P = 0.009 1.22 (0.99, 1.51), P = 0.115
Rituximab 
naïve only
SLE 
n=76
Within-SLE, between 
subtypes
Ratio (90% CI), P value
HC 
n=17
Between-group 
SLE:HC 
Ratio (90% CI), P value
Between-group, between 
subtype
Ratio (90% CI), P value
Monocytes 3206 Reference 2949 1.09 (0.80, 1.48), P = 0.657 Reference
T-cells 666 0.21 (0.19, 0.23), P < 0.001 494 1.35 (1.07, 1.70), P = 0.034 1.24 (1.01, 1.52), P = 0.080
NK-cells 1068 0.33 (0.31, 0.36), P < 0.001 857 1.25 (0.98, 1.58), P = 0.129 1.15 (0.93, 1.41), P = 0.271
Naïve B-cells 1132 0.35 (0.32, 0.39), P < 0.001 740 1.53 (1.20, 1.95), P = 0.004 1.41 (1.15, 1.73), P = 0.006
Memory B-cells 1574 0.49 (0.45, 0.53), P < 0.001 1074 1.47 (1.17, 1.83), P = 0.005 1.35 (1.11, 1.64), P = 0.013
Plasmablasts 2597 0.81 (0.74, 0.89), P < 0.001 1885 1.38 (1.08, 1.76), P = 0.033 1.27 (1.02, 1.57), P = 0.068
Values under SLE and HC show age-adjusted mean tetherin protein levels compared 
within SLE patients and between SLE patients and controls. The tetherin cell protein data 
were ln-transformed prior to analysis, therefore the back-transformed results represent 
ratios of values in each of the subtypes relative to monocytes within SLE patients, and 
the ratio of SLE patients to HC in each of the subtypes. Interaction ratios express the 
ratio of the extent of the difference between SLE and HC in each subset relative to 
monocytes
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Table 2: Association between candidate IFN assays and plasmablast level 
following B-cell depletion therapy
Plasmablast Count (cells x 109/L)
Pre-rituximab
(n = 50)
Post-rituximab
(n = 28)
Interferon Score A -0.11, P = 0.448 0.24, P = 0.219
Tetherin protein level:
Monocytes -0.08, P = 0.592 0.20, P = 0.296
T-cells -0.16, P = 0.269 0.32, P = 0.096
NK-cells -0.14, P = 0.324 0.05, P = 0.795
Naïve B-cells -0.04, P = 0.801 0.30, P = 0.121
Memory B-cells 0.07, P = 0.618 0.38, P = 0.047
Values are Spearman’s Rank Correlation Coefficient and P values for correlation 
between plasmablast count and Interferon Scores A and B (measured on unsorted 
PBMCs) as well as tetherin MFI on each cell subset (analyzed using flow cytometry). 
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